Publications
View our recent posters and publications:
Azetukalner in Epilepsy and Related Publications
Peer-Reviewed Journal Article in Epilepsia Open. French JA, Porter RJ, Perucca E, Brodie MJ, Rogawski MA, Harden C, et al. Interim analysis of the long-term efficacy and safety of azetukalner in an ongoing open-label extension study following a phase 2b clinical trial (X-TOLE) in adults with focal epilepsy. Epilepsia Open. Published online March 7, 2025.
Company Poster. “Long-Term Safety and Efficacy of Azetukalner, a Novel, Potent Kv7 Potassium Channel Opener in Adults With Focal Epilepsy: Update From the Ongoing 7-Year Open-Label Extension of X-TOLE” 2025 Annual Meeting of the American Academy of Neurology (AAN). April 5-9, 2025
Company Poster. “Is the Mental Health Burden of Epilepsy Under-Recognized in Patients Reporting Focal Onset Seizures? A Patient-Reported Outcomes Study” 2025 Annual Meeting of the American Academy of Neurology (AAN). April 5-9, 2025
Company Poster. “Efficacy of Azetukalner in Focal Onset Seizure (FOS) Subtypes: Results From the Double-Blind, Placebo Controlled X-TOLE Study” 2025 Annual Meeting of the American Academy of Neurology (AAN). April 5-9, 2025
Company Poster. “A Targeted Literature Review of Comorbidity Burden in Focal Onset Seizures” 2024 Annual Meeting of the American Epilepsy Society (AES). December 6-10, 2024
Peer-Reviewed Journal Article in JAMA Neurology. French JA, Porter RJ, Perucca E, et al. Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial. JAMA Neurol. Published online October 09, 2023.
Azetukalner in MDD
Company Poster. “Efficacy and Safety of Azetukalner, a Novel, Potent KV7 Potassium Channel Opener in Adults With Moderate to Severe Major Depressive Disorder: Results From the Proof-of-Concept Phase 2 X-NOVA Study” Psych Congress. October 31, 2024
Other
Company Poster. “Azetukalner, a Novel, Potent Kv7 Potassium Channel Opener in Development for the Treatment of Focal Onset Seizures, Primary Generalized Tonic‑Clonic Seizures, and Major Depressive Disorder” American Society for Experimental Neurotherapeutics Annual Meeting. March 12-14, 2025
Xenon’s Pre-Clinical Programs
Company Poster. “Nav1.1 Potentiators Modulate Brain Rhythms Measured Through Quantitative Electrocorticography (qECoG) in a Dravet Mouse Model” 2024 Annual Meeting of the American Epilepsy Society (AES). December 6-10, 2024
Company Poster. “Selective Potentiation of Nav1.1 Channels in Dravet Mice Restores Interneuron Function and Improves Motor Function” 2024 Annual Meeting of the American Epilepsy Society (AES). December 6-10, 2024
View our Publications Archive